Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results from 588,398 Procedures in the National Cardiovascular Data Registry
Overview
Authors
Affiliations
Objectives: We sought to create contemporary models for predicting mortality risk following percutaneous coronary intervention (PCI).
Background: There is a need to identify PCI risk factors and accurately quantify procedural risks to facilitate comparative effectiveness research, provider comparisons, and informed patient decision making.
Methods: Data from 181,775 procedures performed from January 2004 to March 2006 were used to develop risk models based on pre-procedural and/or angiographic factors using logistic regression. These models were independently evaluated in 2 validation cohorts: contemporary (n = 121,183, January 2004 to March 2006) and prospective (n = 285,440, March 2006 to March 2007).
Results: Overall, PCI in-hospital mortality was 1.27%, ranging from 0.65% in elective PCI to 4.81% in ST-segment elevation myocardial infarction patients. Multiple pre-procedural clinical factors were significantly associated with in-hospital mortality. Angiographic variables provided only modest incremental information to pre-procedural risk assessments. The overall National Cardiovascular Data Registry (NCDR) model, as well as a simplified NCDR risk score (based on 8 key pre-procedure factors), had excellent discrimination (c-index: 0.93 and 0.91, respectively). Discrimination and calibration of both risk tools were retained among specific patient subgroups, in the validation samples, and when used to estimate 30-day mortality rates among Medicare patients.
Conclusions: Risks for early mortality following PCI can be accurately predicted in contemporary practice. Incorporation of such risk tools should facilitate research, clinical decisions, and policy applications.
Chen K, Huang Y, Liu C, Li S, Chen M BMC Health Serv Res. 2025; 25(1):105.
PMID: 39833782 PMC: 11744989. DOI: 10.1186/s12913-025-12218-6.
Institution of a formal multidisciplinary heart team for high-risk coronary revascularization.
Potluri S, Sawhney R, Dorton C, McCullough K, Moubarak G, Shih E Proc (Bayl Univ Med Cent). 2024; 38(1):28-33.
PMID: 39712420 PMC: 11657062. DOI: 10.1080/08998280.2024.2426925.
Dabrowski E, Kralisz P, Nowak K, Gugala K, Prokopczuk P, Mezynski G J Clin Med. 2024; 13(22).
PMID: 39598051 PMC: 11595233. DOI: 10.3390/jcm13226907.
Should We Use Aspirin or P2Y Inhibitor Monotherapy in Stable Ischemic Heart Disease?.
Chandiramani R, Mehta A, Blumenthal R, Williams M Curr Atheroscler Rep. 2024; 26(11):649-658.
PMID: 39243345 DOI: 10.1007/s11883-024-01234-2.
Assessing Quality in Interventional Practice: Identifying Meaningful and Actionable Metrics.
Klein L Rev Cardiovasc Med. 2024; 25(2):58.
PMID: 39077330 PMC: 11263148. DOI: 10.31083/j.rcm2502058.